Clinical Trial

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-02.
Status change: Not Yet Recruiting → Recruiting 2025-05-02
Trial Details
NCT Number NCT06401824
Lead Sponsor Maastricht University Medical Center
Collaborators: Gilead Sciences
Conditions NSCLC Stage IV, Brain Metastases, Adult
Enrollment 25 participants
Start Date 2025-04-24
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-06